Compare · DXCM vs WOK
DXCM vs WOK
Side-by-side comparison of DexCom Inc. (DXCM) and WORK Medical Technology Group LTD (WOK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and WOK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $29.57B, about 171262.7x WOK ($172,633).
- Over the past year, DXCM is down 10.6% and WOK is down 100.0% - DXCM leads by 89.4 points.
- DXCM has been more active in the news (26 items in the past 4 weeks vs 16 for WOK).
- DXCM has more recent analyst coverage (25 ratings vs 0 for WOK).
- Company
- DexCom Inc.
- WORK Medical Technology Group LTD
- Price
- -
- -
- Market cap
- $29.57B
- $172,633
- 1M return
- +25.71%
- -92.32%
- 1Y return
- -10.56%
- -100.00%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2024
- News (4w)
- 26
- 16
- Recent ratings
- 25
- 0
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest DXCM
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
- Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
- Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
- Director Altman Steven R was granted 5,565 shares (SEC Form 4)
- Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)
- Director Malady Kyle was granted 5,575 shares, increasing direct ownership by 25% to 28,242 units (SEC Form 4)
- Director Heller Bridgette P was granted 5,575 shares, increasing direct ownership by 22% to 30,582 units (SEC Form 4)
- Director Osterloh Albert Frederick Iv was granted 1,630 shares, increasing direct ownership by 23% to 8,691 units (SEC Form 4)
- Director Foletta Mark G was granted 6,331 shares (SEC Form 4)
Latest WOK
- Large owner Hrt Financial Lp bought $148,922 worth of shares (1,424,537 units at $0.10) (SEC Form 4)
- New insider Hrt Financial Lp claimed ownership of 331,652 shares (SEC Form 3)
- SEC Form 6-K filed by WORK Medical Technology Group LTD
- WORK Medical Technology Group Participated in 2026 CBA-China Annual Conference
- Large owner Hrt Financial Lp bought $378,994 worth of shares (2,746,332 units at $0.14) and sold $188,101 worth of shares (1,757,955 units at $0.11) (SEC Form 4)
- New insider Hrt Financial Lp claimed ownership of 351,959 shares (SEC Form 3)
- WORK Medical Technology Group Establishes U.S. Subsidiary to Advance Global Expansion and Reinforce Long-Term Growth Strategy
- SEC Form 3 filed by new insider Johnson Robert Brian
- Large owner Hrt Financial Lp bought $138,226 worth of shares (1,535,850 units at $0.09) and sold $261,961 worth of shares (2,619,607 units at $0.10) (SEC Form 4)
- New insider Hrt Financial Lp claimed ownership of 225,234 shares (SEC Form 3)